Effect of ＂Pleurotus tuber-regium＂ Polysaccharides Supplementation on the Progression of Diabetes Complications in Obese-Diabetic Rats

Hui-Yu Huang ； Mallikarjuna Korivi ； Hui-Ting Yang ； Chi-Chang Huang ； Ying-Ying Chaing ； Ying-Chieh Tsai

《The Chinese Journal of Physiology》 57卷4期 (2014/08) Pp. 198-208

https://doi.org/10.4077/CJP.2014.BAC245

並列摘要

In this study, the effect of mushroom extracellular polysaccharides on fatty acid composition and liver peroxisome proliferator-activated receptor-alpha (PPAR-α) expression in obese-diabetic rats was investigated, and distinguished the association among anti-obesity, hypoglycemic and hypolipidemic properties. Extracellular polysaccharides from three different strains of Pleurotus tuber-regium were extracted and labeled as HP (high-percentage), MP (medium-percentage) and LP (low-percentage). Obesediabetes (OD) was induced by chronic high-fat diet plus streptozotocin (STZ) injections. Simultaneously to the diet, polysaccharides were orally administered to OD groups (20 mg/kg body weight/8-week), and categorized into OD+HP, OD+MP and OD+LP groups (n = 10/group), respectively. High-fat diet plus STZ-induced hyperglycemia was prominently attenuated by polysaccharides. Increased fatty acid component n-6/n-3 ratio in liver and plasma of obese-diabetic rats was attenuated, while, reduced MUFA/PUFA and MUFA/SFA ratios were restored (P ＜ 0.01) with polysaccharides treatment. Furthermore, elevated serum total cholesterol, triglycerides and low-density lipoprotein (LDL) concentrations were controlled, and parallel restoration of decreased high-density lipoprotein (HDL) levels were found with polysaccharides supplementation. This hypolipidemic property might be associated with up-regulated liver PPAR-α mRNA expression and protein levels (P ＜ 0.01). These findings concluded that stable fatty acid components and activated PPAR-α by polysaccharides may contribute to its hypoglycemic and hypolipidemic properties. Therefore, P. tuber-regium could be considered as nutritional supplement to treat diabetic complications.

並列關鍵字

dyslipidemia ； fatty acid composition ； hyperglycemia ； mushroom ； obesity

參考文獻

Athyros, V.G.,Tziomalos, K.,Karagiannis, A.,Anagnostis, P.,Mikhailidis, D.P.(2010).Should adipokines be considered in the choice of the treatment of obesity-related health problems?.Curr. Drug Targets.11,122-135.

Berger, J.P.,Akiyama, T.E.,Meinke, P.T.(2005).PPARs: therapeutic targets for metabolic disease.Trends Pharmacol. Sci..26,244-251.

Brooks, N.L.,Moore, K.S.,Clark, R.D.,Perfetti, M.T.,Trent, C.M.,Combs, T.P.(2007).Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome?.Diabetes Obes. Metab..9,246-257.

Chang, R.(1996).Functional properties of edible mushrooms.Nutr. Rev..54,S91-S93.

Chen, S.C.,Liao, C.A.,Lee, S.D.,Chen, Y.L.,Lin, C.T.,Kao, C.L.,Kuo, C.H.(2012).Cross-generation link between inactive behavior of schoolchildren and metabolic disease category of parents.Chinese J. Physiol..55,108-113.